Retrospective and prospective evaluation of the pharmacogenetics and metabolites of thiopurine drugs in the treatment of inflammatory bowel disease: a self-controlled trial and a randomised controlled trial

Sun Yat-sen University (China)0 个研究点目标入组 170 人开始时间: 2010年1月19日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. All consecutive patients with the diagnosis of IBD who received the azathioprine treatment at the Gastroenterology Outpatient Clinic of the First Affiliated Hospital of Sun Yat-sen University
•2. Aged from 3 - 74 years, either sex
•3. Steroid-dependent disease: unable to reduce corticosteroids below the equivalent of prednisolone 15 mg/day (or budesonide below 3 mg/day) within three months of starting corticosteroids or relapse within three months of stopping corticosteroids
•4. Frequent relapses: greater than three relapses in one year or greater than two relapses in six months
•5. Remission maintenance
•6. Post-operative prophylaxis

•1. Blood transfusion or administration of cyclosporine or methotrexate (MTX) within the last 3 months
•2. Treatments potentially interfering with AZA metabolism, including allopurinol and diuretics
•3. Insufficient function in heart, liver or kidney
•4. Active infection
•5. Pregnancy

发起方

Sun Yat-sen University (China)